LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1,235.69% | 24.95% | -81.56% | 77.75% | -64.32% |
| Total Depreciation and Amortization | 30.75% | 2.61% | 2.10% | 38.15% | -30.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -968.69% | -39.11% | 66.60% | -86.13% | 671.28% |
| Change in Net Operating Assets | 40.19% | 25.98% | 71.00% | -6.26% | 6.99% |
| Cash from Operations | 606.11% | 18.41% | 94.48% | -14,857.29% | 100.53% |
| Capital Expenditure | 187.17% | -29.16% | -68.55% | -349.05% | 35.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -3,536.82% | 98.57% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,118.06% | 17.52% | -37.03% | 52.62% | -1,129.03% |
| Cash from Investing | -49.48% | 56.83% | -362.94% | -60.54% | -102.35% |
| Total Debt Issued | 255.50% | 300.68% | -65.18% | 59.85% | -73.21% |
| Total Debt Repaid | -306.69% | 18.07% | -165.45% | 62.39% | -609.09% |
| Issuance of Common Stock | -100.00% | -81.84% | 166.25% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.51% | 54.67% | -262.86% | -129.13% | 223.68% |
| Cash from Financing | 30.65% | -62.92% | 41.21% | 463.67% | -78.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 202.95% | -138.93% | 874.01% | -208.96% | 106.87% |